microRNA-based cancer therapeutics
| Date | Round | Amount |
|---|---|---|
| Feb 2021 | Series B Dutch biotech InteRNA Technologies closed a EUR18.5M Series B led by AurorA Science, with Waterman Ventures, Aglaia Oncology Funds and OostNL. | $18.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.